Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, announced yesterday that it presented new data on its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th Annual World ADC London conference. The presentation, titled "Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies," was delivered by Jonathan Davis, PhD, Director of ADC Discovery at Helix BioPharma, as part of the conference's Seminar Day program.
The presentation highlighted CEACAM6 as a highly attractive therapeutic target due to its elevated expression across a broad range of epithelial cancers, its association with poor clinical outcomes, and its limited expression in healthy tissues. Dr. Davis presented data supporting the tumor-selective binding profile of Helix's proprietary anti-CEACAM6 VHH, a single-domain antibody fragment derived from camelid antibodies, which demonstrated preferential binding to tumor-expressed CEACAM6. This highly selective binding profile supports the development of next-generation ADCs designed to deliver potent therapeutic payloads directly to cancer cells while minimizing off-target effects.
The program builds on the clinical foundation set by Tumor Defense Breaker™, L-DOS47, Helix's lead CEACAM6-targeted candidate, which has demonstrated favorable safety and encouraging clinical activity in Phase I/II studies in non-small cell lung cancer (NSCLC). According to Dr. Davis, "CEACAM6 represents a compelling and underexploited target with broad potential across multiple hard-to-treat cancers. Our proprietary VHH-based targeting approach enables highly selective tumor binding, supporting the development of next-generation ADCs designed to maximize therapeutic impact while minimizing off-target effects."
The World ADC London conference, now in its 16th year, is the longest-standing global conference dedicated to ADC research and development. It brings together over 700 industry stakeholders from more than 240 companies, including biopharma organizations, clinicians, investors, and regulatory experts. A copy of Dr. Davis's presentation is available on the Company's website at https://helixbiopharma.com/wp-content/uploads/2026/02/Unlocking-the-Potential-of-CEACAM6.pdf.
Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today's hardest-to-treat cancers. The Company's pipeline includes L-DOS47, LEUMUNA™, and GEMCEDA™. For more information, visit https://www.helixbiopharma.com/.
